{
  "extraction_metadata": {
    "timestamp": "2025-10-02T18:18:55.861975",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 11,
    "temperature": 0.1
  },
  "outcomes_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "Outcomes": "all-cause mortality, overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, post-treatment complications, liver failure, pain (EORTC QLQ-HCC18), fatigue (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), EORTC QLQ-C30, EORTC QLQ-HCC18, European Quality of Life – 5 Dimensions Visual Analogue Scale (EQ-5D VAS), health status, global health status, function scales of EORTC QLQ-C30, function scales of EORTC QLQ-HCC18, disease recurrence, length of hospital stay, complications",
      "ChunksUsed": 10,
      "ContextTokens": 1974
    },
    "CZ": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "CZ",
      "Outcomes": "",
      "ChunksUsed": 1,
      "ContextTokens": 202
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "Outcomes": "all-cause mortality, overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), mortality, disease recurrence, length of hospital stay, complications, symptoms, health status, health-related quality of life, pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), fatigue (EORTC QLQ-HCC18), diarrhoea, hand-foot skin reaction, hypertension, skin rash, desquamation, liver failure, post-treatment complications, EORTC QLQ-C30, EORTC QLQ-HCC18, European Quality of Life – 5 Dimensions Visual Analogue Scale (EQ-5D VAS)",
      "ChunksUsed": 10,
      "ContextTokens": 2102
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), progression-free survival (PFS; RECIST 1.1), time to progression (TTP), objective response rate (ORR), tumour response rate, complete response (CR), partial response (PR), time to response, duration of response (DoR), disease control rate (DCR; mRECIST), clinical benefit rate (CBR), adverse events (general), serious adverse events, adverse events leading to discontinuation, diarrhoea, nutrition (EORTC QLQ-HCC18), pain (EORTC QLQ-C30), body image (EORTC QLQ-HCC18), role functioning (EORTC QLQ-C30), health-related quality of life (HRQoL), EORTC QLQ-C30, EORTC QLQ-HCC18, EQ-5D, plasma pharmacokinetics lenvatinib exposure parameters, blood and tumour biomarkers, quality-adjusted life years (QALYs), cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
      "ChunksUsed": 10,
      "ContextTokens": 2243
    },
    "EN": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EN",
      "Outcomes": "overall survival, progression-free survival, adverse events, health-related quality of life, cost-effectiveness (incremental cost-effectiveness ratio, ICER), quality-adjusted life years (QALYs)",
      "ChunksUsed": 10,
      "ContextTokens": 1788
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "Outcomes": "overall survival (OS; time from randomisation to death from any cause), progression-free survival (PFS; time from randomisation to tumour progression defined by RECIST 1.1 or death from any cause), objective response rate (ORR; percentage of patients with partial or complete response; RECIST 1.1), objective response rate (ORR; percentage of patients with partial or complete response; modified RECIST for liver disease, mRECIST), duration of response (DoR; time from partial or complete response to disease progression or exit), deterioration in patient quality of life (based on EORTC QLQ-C30), deterioration in patient quality of life (based on EORTC QLQ-HCC18), time to patient-reported impairment of quality of life (EORTC QLQ-C30), time to patient-reported impairment of quality of life (EORTC QLQ-HCC18), time to patient-reported impairment of quality of life (EORTC QLQ-C30 functional role subscale), serious adverse events, grade 5 adverse events, dose modification due to adverse events, drug discontinuation due to adverse events",
      "ChunksUsed": 10,
      "ContextTokens": 3097
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), progression-free survival (RECIST 1.1), time to progression, objective response rate (ORR), disease control rate, clinical benefit rate, hepatotoxicity, hypertension, loss of appetite, weight loss, serious adverse events, grade 3 adverse reactions, treatment-related deaths, significant haemorrhagic events, significant thromboembolic events, hypothyroidism, adverse events (general), EQ5D-3L",
      "ChunksUsed": 10,
      "ContextTokens": 2372
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "Outcomes": "overall survival, time to symptom progression, time to progression, disease control, partial response, minor response (reduction of tumour size by 25 to 50%), stable disease (for at least 16 weeks), fatigue, bleeding, abdominal pain, hypertension, diarrhoea, lymphoedema, hand feeding reactions, adverse reactions (general), serious adverse reactions (grade 3/4), cost-effectiveness analysis",
      "ChunksUsed": 10,
      "ContextTokens": 1717
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), complete response (CR), partial response (PR), stable disease (SD), disease control rate (DCR), number needed to harm (NNH), number needed to treat (NNT), hazard ratio (HR), mean difference (MD), relative risk (RR), risk difference (RD), hand-foot skin reaction, diarrhoea, rash, skin desquamation, fatigue, weight loss, hypertension, decreased appetite, hypocalcaemia, increased ALT activity, secondary cancer, dyspnoea, pleural effusion, alopecia, cough, back pain, limb pain, adverse events (general), EQ-5D (Euro QoL – 5 dimensions), EQ VAS (Euro QoL visual analogue scale), FACT-G (Functional Assessment of Cancer Therapy – General)",
      "ChunksUsed": 10,
      "ContextTokens": 2580
    },
    "PT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PT",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), quality of life, pharmacokinetic parameters, vital signs, laboratory haematological testing, laboratory biochemical testing, urinalysis, electrocardiography, adverse events (graded by National Cancer Institute), adverse events (grade 3 or higher), fatal adverse events, tumour haemorrhage, ischaemic stroke, respiratory failure, sudden death, EORTC QLQ-C30, EORTC QLQ-HCC18",
      "ChunksUsed": 10,
      "ContextTokens": 2163
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "Outcomes": "overall survival (OS; time from randomization to death from any cause), progression-free survival (PFS), objective tumour response, time to tumour progression, quality of life weights, adverse reactions of grade 3 or higher, Eastern Cooperative Oncology Group Performance Status (ECOG PS), tumour spread (TNM system), liver function (Child-Pugh scale), Barcelona Clinic Liver Cancer (BCLC) staging system, cost-benefit analysis, health state utility values",
      "ChunksUsed": 10,
      "ContextTokens": 1844
    }
  }
}